Pfizer COVID-19 Vaccines 73 Percent Protective in Under 5s

WEDNESDAY, Aug. 24, 2022 (HealthDay News) -- The Pfizer modified COVID-19 vaccine for use in children younger than 5 years was 73 percent effective in shielding them from infection during the omicron surge this spring, company data released Tuesday show.
The specially formulated doses for America's youngest children were approved for distribution in June, although the American Academy of Pediatrics says uptake has been low. Just 6 percent of children younger than 5 years had gotten immunized by mid-August, the group said.
At the time of approval, the only studies supporting their use in small children were based on levels of antibodies triggered by the shots. The new data show that the Pfizer vaccine does appear to protect young children well against symptomatic COVID-19.
In the new study -- conducted between March and June of this year, when the BA.2 omicron variant was dominant -- 13 of 794 children younger than 5 years who got the new three-dose vaccine got symptomatic COVID-19 compared with 21 cases among the 351 children who received a dummy placebo shot, Pfizer reported.
BA.5 is now the dominant variant, accounting for nearly 90 percent of all new U.S. cases. However, studies in older children and adults are showing that the COVID-19 vaccine is shielding people against severe disease -- cases causing hospitalization and death -- even as the virus mutates.
Related Posts
Health Highlights: Oct. 29, 2021
Magnetic brain stimulation therapy offers hope against severe depression....
La FDA aprueba los refuerzos bivalentes contra la COVID para los niños de a partir de 6 meses
JUEVES, 8 de diciembre de 2022 (HealthDay News) -- Los refuerzos bivalentes...
¿Quiere dejar de beber café, pero le da miedo la abstinencia? Pruebe con el descafeinado
VIERNES, 17 de febrero de 2023 (HealthDay News) -- Los investigadores quizá...
Weight Main Factor Impacting QoL After Single-Anastomosis Duodeno-Ileal Bypass
WEDNESDAY, April 5, 2023 (HealthDay News) -- For patients undergoing...
